| 摘要: |
| 目的 分析激素受体阳性乳腺癌患者预后影响因素并为乳腺癌的临床治疗提供帮助。方 法根据入组标准收集2006 年1 月1日至2008 年12 月31 日收治的激素受体阳性乳腺癌患者285 例，并回顾性分析285 例乳腺癌患者的临床病理特点、治疗方式与患者无病生存率（disease free survival，DFS）与总生存率（overall survival，OS）之间的关系，探究其预后的影响因素。结果 随访的285 例中，5年DFS 为90.3%，5 年OS 为94.6%。年龄≤35 岁患者相比35~60 岁患者DFS 与OS 均缩短（P＜0.01）。淋巴结未转移患者比转移患者预后更佳（P＜0.01）。术后辅助化疗、术后辅助放疗、内分泌治疗可显著改善患者的DFS 及OS（P＜0.01）。间断或中断内分泌治疗能影响患者DFS 与OS（P＜0.01）。中药巩固治疗能改善患者DFS（P＜0.05），但未能影响OS。结论 淋巴结转移是全组患者的不良预后因素。辅助化疗、辅助放疗、内分泌治疗均能改善激素受体阳性乳腺癌的生存，加强术后的个体化管理对规范内分泌治疗意义重大。 |
| 关键词: 乳腺癌 激素受体阳性 随访 复发转移 |
| DOI： |
| 分类号: |
| 基金项目: |
|
| Prognosis-related factors of patients with hormone receptor-positive breast cancer |
|
CHEN Jianbin, WANG Bei, GAO Xiufei
|
|
the First Clinical Medical College of Zhejiang Chinese Medical University
|
| Abstract: |
| Objective To assess the prognosis related factors of patients with hormone receptor-positive breast cancer. Methods Clinicopathological data of 285 patients with hormone receptor-positive breast cancer admitted from January 2006 to December 2008 were retrospectively reviewed. The risk factors related to disease-free survival (DFS) and Overall survival (OS) were analyzed. Results The 5-y DFS and 5-y OS was 90.3% and 94.6% in 285 patients, respectively. the age≤35 patients have worse DFS and OS than others.(P＜0.01) OS is 77.8%、96.9%、93.0%respectively.(P＜0.01) The DFS and OS in patients with axillary node metastasis were shorter than those in patients without metastasis (83.3%vs 95.3%and 89.5%vs 98.2%respectively, all P＜0.01). There were no significant differences in DFS and OS between patients with KI-67 positive and those with negative KI-67 (P＞0.05). Postoperative adjuvant chemotherapy, postoperative auxiliary radiotherapy and endocrine therapy improved both DFS and OS of patients significantly (P＜0.01). Compared to consistent endocrine therapy, the interruption of therapy shortened both DFS and OS (94.1%vs 78.4% and 97.4%vs 86.5%, respectively, all P＜0.01). Traditional Chinese medicine treatment improved DFS(P＜0.05), but failed to affect the OS. Conclusion Age ≤35 y and axillary node metastasis are risk factors for poor prognosis; adjuvant chemotherapy, adjuvant radiotherapy and endocrine therapy can improve the survival of patients with hormone receptor-positive breast cancer. |
| Key words: Breast cancer Hormone receptor-positive Follow-up Recurrence and metastasis |
